Opus Genetics, Inc. Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross
Opus Genetics, Inc. (IRD) reported Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross of $30.00 million for the 9-month period ending 2014-09-30, per its 10-Q filed 2014-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross · last filed 2014-11-12
- Opus Genetics, Inc. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2014-09-30 was $1.80M, a 189.05% increase year-over-year.
- Opus Genetics, Inc. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2014-06-30 was $1.99M, a 134.83% increase year-over-year.
- Opus Genetics, Inc. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2014-03-31 was $26.21M, a 30.79% increase year-over-year.
- Opus Genetics, Inc. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2013-12-31 was $1.46M, a 122.36% increase year-over-year.
- Opus Genetics, Inc. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2013 was $22.97M, a 16.56% increase from fiscal 2012.
- Opus Genetics, Inc. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2012 was $19.71M.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 3 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 6 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 9 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 12 month |
|---|---|---|---|---|
| 2014-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $3.79M derived: sum of 2 quarters · filed 2014-11-12 | $30.00M 10-Q · filed 2014-11-12 | $31.46M derived: sum of 4 quarters · filed 2014-11-12 |
| 2014-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-13 | $28.20M 10-Q · filed 2014-08-13 | $29.66M derived: sum of 3 quarters · filed 2014-08-13 | $30.28M derived: sum of 4 quarters · filed 2014-08-13 |
| 2014-03-31 | $26.21M 10-Q · filed 2014-05-14 | $27.67M derived: sum of 2 quarters · filed 2014-05-14 | $28.29M derived: sum of 3 quarters · filed 2014-05-14 | $29.14M derived: sum of 4 quarters · filed 2014-05-14 |
| 2013-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $2.08M derived: sum of 2 quarters · filed 2014-03-21 | $2.93M derived: sum of 3 quarters · filed 2014-03-21 | $22.97M 10-K · filed 2014-03-21 |
| 2013-09-30 | $622.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $1.47M derived: sum of 2 quarters · filed 2013-11-13 | $21.51M 10-Q · filed 2013-11-13 | $22.17M derived: sum of 4 quarters · filed 2013-11-13 |
| 2013-06-30 | $846.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-12 | $20.89M 10-Q · filed 2013-08-12 | $21.54M derived: sum of 3 quarters · filed 2013-08-12 | $20.64M derived: sum of 4 quarters · filed 2013-08-12 |
| 2013-03-31 | $20.04M 10-Q · filed 2013-05-09 | $20.70M derived: sum of 2 quarters · filed 2013-05-09 | $19.79M derived: sum of 3 quarters · filed 2013-05-09 | |
| 2012-12-31 | $655.25K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22 | -$250.17K derived: sum of 2 quarters · filed 2013-03-22 | $19.71M 10-K · filed 2013-03-22 | |
| 2012-09-30 | -$905.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $19.05M 10-Q · filed 2012-11-08 | ||
| 2012-06-30 | $19.96M 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |